

 <p>Substitute Form PTO-1449 (Modified)</p> <p>SEP 17 2007</p> <p>PATENT & TRADEMARK OFFICE (37 CFR) § 1.98(b))</p>	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 20750-007US1	Application No. 10/541,657
	Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Arena Pharmaceuticals, Inc.	
			Filing Date March 3, 2006	Group Art Unit 1624

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AI	EP 1287133	03/05/2003	Europe			
	AJ						
	AK						
	AL						
	AM						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AN	Abstract #107, p.56, <i>Toward Understanding Islet Biology</i> , January 21, 2003 – January 26, 2003, Keystone, Colorado.
	AO	Abstract #112, p.42, <i>Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies</i> , January 27, 2005 – February 2, 2005, Keystone, Colorado.
	AP	Abstract #228, p.54, <i>Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies</i> , January 27, 2005 – February 2, 2005, Keystone, Colorado.
	AQ	Abstract #117 & Poster, <i>Diabetes: Molecular Genetics, Signaling Pathways and Integrated Physiology</i> , January 14, 2007 – January 19, 2007, Keystone, Colorado
	AR	Abstract #230 & Poster, <i>Diabetes: Molecular Genetics, Signaling Pathways and Integrated Physiology</i> , January 14, 2007 – January 19, 2007, Keystone, Colorado
	AS	Chu et al., "A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release," <i>Endocrinology</i> (2007) 148:2601-2609.
	AT	Fyfe et al., <i>Diabetes</i> (2007) 56(Supplement 1):A142 (Abstract #532-P).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-007US1	Application No. 10/541,657
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Arena Pharmaceuticals, Inc.	
		Filing Date March 3, 2006	Group Art Unit 1624

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AU	Overton et al., "Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents," <i>Cell Metabolism</i> (2006) 3:167-175.
	AV	Soga et al., "Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor," <i>Biochem Biophys Res Commun</i> (2005) 326:744-751.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	